Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Arch Pediatr ; 23(11): 1191-1200, 2016 Nov.
Artículo en Francés | MEDLINE | ID: mdl-27743765

RESUMEN

These guidelines are intended to assist physicians in the care of children with chronic kidney disease (CKD), defined in children as in adults, regardless of its cause. Often silent for a long time, CKD can evolve to chronic renal failure or end-stage renal disease. Its management aims at slowing disease progression and treating CKD complications as soon as they appear. The different aspects of pediatric CKD care are addressed in these guidelines (screening, treatment, monitoring, diet, quality of life) as proposed by the French Society of Pediatric Nephrology. Highly specialized care provided in the hospital setting by pediatric nephrologists is not detailed.


Asunto(s)
Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/terapia , Albuminuria/etiología , Albuminuria/terapia , Anemia/etiología , Enfermedades Óseas Metabólicas/etiología , Enfermedades Óseas Metabólicas/terapia , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/terapia , Niño , Trastornos de la Nutrición del Niño/etiología , Trastornos de la Nutrición del Niño/terapia , Manejo de la Enfermedad , Tasa de Filtración Glomerular , Hemoglobinas/análisis , Humanos , Tamizaje Masivo , Infecciones Oportunistas/prevención & control , Proteinuria/etiología , Proteinuria/terapia , Calidad de Vida , Valores de Referencia , Insuficiencia Renal Crónica/complicaciones , Vacunación
2.
Eur J Pediatr ; 174(1): 23-32, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24953377

RESUMEN

UNLABELLED: Renovascular hypertension accounts for 5-10 % of hypertension cases in children; there is currently no consensus on treatment. Here, we report on our clinical experience with this disease and outline the different pathways in which to investigate it. We report retrospectively on ten children diagnosed with renovascular hypertension at the University Hospital of Nantes from 2001 to 2012. The main findings were obtained by fortuitous screening of children aged 2 months to 14 years old with neurofibromatosis (n = 2) and fibromuscular dysplasia (n = 8). The hypertension was always severe yet asymptomatic. Lesions were complicated in nine out of ten cases and included bilateral, multiple, mid-aortic syndrome and aneurysm. Doppler ultrasound associated with computed tomography allowed for a precise diagnosis in seven out of ten cases. Where ambiguities persisted, they were highlighted by arteriography, the gold standard investigation. Medical treatment was insufficient, leading to invasive procedures in nine out of ten children: 2 nephrectomies, 2 autotransplantations, and 21 repetitive percutaneous transluminal angioplasties. After invasive procedures, blood pressure control improved in four cases and was resolved in three. CONCLUSION: Arteriography remains to be the gold standard technique for renovascular hypertension in children and can be combined with angioplasty when medical treatment is rendered obsolete. The role of computed tomography is controversial. Despite the heterogeneity of the children studied, we present a general medical and therapeutic management pathway for the treatment of this disease.


Asunto(s)
Hipertensión Renovascular/diagnóstico , Hipertensión Renovascular/terapia , Adolescente , Angiografía/métodos , Angioplastia , Niño , Preescolar , Femenino , Displasia Fibromuscular/complicaciones , Humanos , Lactante , Masculino , Neurofibromatosis 1/complicaciones , Sistema Renina-Angiotensina/fisiología , Estudios Retrospectivos , Tomografía Computarizada por Rayos X/métodos , Ultrasonografía Doppler
3.
Pediatr Transplant ; 17(6): E131-6, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23834525

RESUMEN

Bortezomib has appeared recently as a potential active treatment for acute AMR for few years. We reported a patient who received two courses of bortezomib for the treatment of an acute AMR associated with de novo HLA DSA that occurred 18 months after renal transplantation because of non-compliance. Graft biopsy revealed features of acute humoral rejection with plasmocyte infiltration and C4d staining. Bortezomib was associated with corticosteroid pulses, IVIgs, and PP. Despite this rapid management, the patient lost his graft and carried on dialysis. Bortezomib therapy in addition to current therapy of AMR is not always effective in the treatment for late acute AMR in renal transplantation. We discuss on the place of such a treatment and other therapeutic strategies in this indication.


Asunto(s)
Anticuerpos/química , Ácidos Borónicos/uso terapéutico , Rechazo de Injerto/tratamiento farmacológico , Trasplante de Riñón/métodos , Riñón Poliquístico Autosómico Recesivo/terapia , Pirazinas/uso terapéutico , Adolescente , Corticoesteroides/uso terapéutico , Biopsia , Bortezomib , Complemento C4b/química , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/química , Masculino , Cooperación del Paciente , Fragmentos de Péptidos/química , Inhibidores de Proteasas/uso terapéutico , Diálisis Renal/métodos , Resultado del Tratamiento
4.
Arch Pediatr ; 18(9): 955-61, 2011 Sep.
Artículo en Francés | MEDLINE | ID: mdl-21795028

RESUMEN

PURPOSE: To compare two first febrile urinary tract infection (UTI) management protocols with regards to the diagnosis of high-grade vesicoureteral reflux (VUR) and cost. METHODS: This study compared two cohorts of children under 16 years of age, admitted for a first episode of febrile UTI. The first group (in 2005) was managed according to previous recommendations (IV treatment and cystography performed for all children under 3 years of age). The second group (in 2006) was managed according to age and procalcitonin level. High-grade VUR frequency, UTI recurrence, hospitalization rate, and cost were compared between the two cohorts. RESULTS: A total of 225 children were included in 2005 and 116 in 2006. High-grade VUR was found in 6.2 and 9.5% of the patients in 2005 and 2006, respectively (P=0.274). There was no statistically significant difference in the UTI recurrence rate between the two cohorts (5.3% in 2005 and 8.6% in 2006; P=0.237). The mean cost of an episode of febrile UTI was not significantly different in 2005 and 2006 (€2235 in 2005, €2256 in 2006; P=0.902), but was lower for children older than 6 months in 2006 (€1292 versus €1882 in 2005; P=0.0042). CONCLUSION: Our management protocol for a first febrile UTI episode in children based on procalcitonin levels seems to be suitable for the diagnosis of high-grade VUR. The hospitalization rate and the mean cost of management for children older than 6 months of age was significantly reduced in 2006. The management guidelines for a first occurrence of febrile UTI in children should be reconsidered.


Asunto(s)
Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/microbiología , Reflujo Vesicoureteral/complicaciones , Reflujo Vesicoureteral/tratamiento farmacológico , Adolescente , Antibacterianos/uso terapéutico , Biomarcadores/orina , Calcitonina/orina , Péptido Relacionado con Gen de Calcitonina , Niño , Preescolar , Estudios de Cohortes , Femenino , Fiebre/microbiología , Francia , Humanos , Lactante , Pacientes Internos , Tiempo de Internación/economía , Masculino , Guías de Práctica Clínica como Asunto , Valor Predictivo de las Pruebas , Precursores de Proteínas/orina , Sensibilidad y Especificidad , Resultado del Tratamiento , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/economía , Infecciones Urinarias/orina , Reflujo Vesicoureteral/diagnóstico , Reflujo Vesicoureteral/economía , Reflujo Vesicoureteral/orina
5.
Pediatr Transplant ; 13(6): 725-30, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19691564

RESUMEN

OBJECTIVE AND METHODS: To assess patient survival in pediatric renal transplantation, we retrospectively reviewed 573 transplants in 553 patients, registered from 1995 to 2005. RESULTS: Mean age at transplantation was 9.9 years. Patient survival at 1, 5 and 10 years was respectively 99%, 97% and 96%. Death occurred at a median time of 2.6 years after transplantation. Long-term patient survival was significantly lower in recipients younger than 5 years old. Seventeen patients (3.1%) died. Two deaths occurred while under maintenance dialysis. Among the remaining patients, the two main causes of death were infections (33%) and malignancies (27%). Interestingly, initial disease-related complications were a major cause of death (34%). CONCLUSION: A low mortality rate was observed, with the majority of deaths due to malignancies and infections, and with a notable participation of complications related to the initial disease. No impact of cardiovascular disease was noted with the given follow-up period. Improvements in managing immunosuppression may contribute to reducing mortality in pediatric renal transplantation.


Asunto(s)
Rechazo de Injerto/mortalidad , Enfermedades Renales/mortalidad , Enfermedades Renales/terapia , Trasplante de Riñón/métodos , Niño , Preescolar , Bases de Datos Factuales , Francia , Humanos , Inmunosupresores/uso terapéutico , Enfermedades Renales/cirugía , Trasplante de Riñón/efectos adversos , Sistema de Registros , Diálisis Renal , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...